News

The approval allows Nuformix to initiate the first dosing of NXP001 in an open-label study to compare the bioavailability of NXP001 to Merck’s EMEND  in healthy subjects. Nuformix

The expanded Farxiga and Xigduo XR labels have been approved to treat patients with T2D and moderate renal impairment, which is a chronic kidney disease with an estimated

New investor Seventure Partners, via its microbiome-focused fund Health for Life Capital™, led the financing along with existing investors Longwood Fund, Domain Associates, Heritage Medical Systems and a

Based in Cambridge of Massachusetts, Anthos Therapeutics will develop and commercialize genetically and pharmacologically validated therapies for high-risk cardiovascular patient populations. Anthos chairman and Blackstone Life Sciences head

“As we continue to transform Bausch Health, we are now pivoting to offense with research investments and strategic acquisitions that augment our core businesses. We are excited to

Imbrium will leverage TetraGenetics’ proprietary TetraExpress system to advance monoclonal antibodies that target specific ion channels that are scientifically important in the modulation of pain sensation. The goal

TQJ230 was discovered by Ionis and has been co-developed to date by Akcea and Ionis. Novartis is now responsible for worldwide development and commercialization of this asset. Millions

THEMIS was conducted in over 19,000 patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior heart attack (myocardial infarction, MI) or stroke. Preliminary safety

As per the terms of the merger agreement, Roche will buy each share of Spark Therapeutics at a price of $114.50. Founded in 2013, Spark Therapeutics is engaged